Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Nab-paclitaxel plus liposomal doxorubicin in advanced vascular tumors

Xing Zhang, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses results from a Phase II study (NCT04859465) evaluating nab-paclitaxel plus pegylated liposomal doxorubicin in patients with advanced or unresectable malignant vascular tumors, predominantly angiosarcoma and epithelioid hemangioendothelioma. The combination achieved high response and disease control rates, with progression-free survival comparing favorably with historical outcomes for single-agent paclitaxel. Toxicity was manageable and mainly low-grade, with hematologic events predominating among higher-grade adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

This is a Phase 2 clinical trial that multicenter. The topic is pegylated liposomal doxorubicin plus non-pegylated paclitaxel in treating unresectable or advanced malignant vascular tumors. This is a Phase 2 clinical trial conducted multicenter. And because we know that malignant vascular tumors remain associated with a very poor prognosis, progression-free survival is very short, and the overall response rate is very low...

This is a Phase 2 clinical trial that multicenter. The topic is pegylated liposomal doxorubicin plus non-pegylated paclitaxel in treating unresectable or advanced malignant vascular tumors. This is a Phase 2 clinical trial conducted multicenter. And because we know that malignant vascular tumors remain associated with a very poor prognosis, progression-free survival is very short, and the overall response rate is very low. So, okay. So we can see that the ORR for anthracyclines is only 20% to 30%, and the ORR for non-pegylated paclitaxel is only 30%. So the ORR is very low. So we are facing treatment options with very low response rates. And the progression-free survival for doxorubicin and paclitaxel is very short, only four months. Progression-free survival is very short. So we need better treatment. So there is an unmet need for treating radiation-induced sarcoma. So we use the combination of the two drugs. Pegylated liposomal doxorubicin can prolong circulation time, increase drug accumulation at the tumor site, and reduce cardiotoxicity, and non-pegylated paclitaxel could increase drug delivery and reduce toxicity. So this combination of the two drugs could increase tumor control, improve drug delivery, and reduce cardiac toxicity. So this is the first Phase 2 clinical trial. And we can see that the aim is to evaluate safety and efficacy. So the dose of doxorubicin is 35 mg/m², and the dose for non-pegylated paclitaxel is 220 mg. So the primary endpoint is ORR, and the secondary endpoints are DCR, PFS, and OS. From that, we can see that the ORR for the cohort is about 50%. The ORR for angiosarcoma is 31.3%, and PFS for the cohort is about eight months. And interestingly, we can see that PFS for angiosarcoma is about 7.3 months. So we can see that this combination achieved an ORR of 50%, or even higher. So from that, we can see that this combination of these two drugs can achieve a higher ORR and longer progression-free survival. So we can see that overall survival is about 28 months. So with the combination of the two drugs, we can achieve a higher ORR of 50%. So from that, in the future, we can plan randomized clinical trials of this combination.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.